Transcriptomics

Dataset Information

31

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis


ABSTRACT: Infliximab, an anti-TNF-alpha monoclonal antibody, is an effective treatment for ulcerative colitis (UC) with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-TNF-alpha is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in UC. Keywords: drug response Overall design: Twenty-four patients with active UC, refractory to corticosteroids and/or immunosuppression, underwent colonoscopy with biopsies from diseased colon within a week prior to the first intravenous infusion of 5 mg infliximab per kg body weight. Response to infliximab was defined as endoscopic and histologic healing at 4-6 weeks after first infliximab treatment. Six control patients with normal colonoscopy were included. Total RNA was isolated from colonic mucosal biopsies, labelled and hybridized to Affymetrix Human Genome U133 Plus 2.0 Arrays.

REANALYSED by: GSE119128

INSTRUMENT(S): [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array

ORGANISM(S): Homo sapiens  

SUBMITTER: Ingrid Arijs   

PROVIDER: GSE14580 | GEO | 2010-01-07

SECONDARY ACCESSION(S): PRJNA111695

REPOSITORIES: GEO

altmetric image

Publications

Sorry, this publication's infomation has not been loaded in the Indexer, please go directly to PUBMED or Altmetric.

Similar Datasets

2015-07-24 | E-GEOD-14580 | ArrayExpress
2015-07-27 | E-GEOD-14580 | ExpressionAtlas
2009-08-25 | GSE12251 | GEO
2015-07-24 | E-GEOD-12251 | ArrayExpress
2015-07-24 | E-GEOD-16879 | ArrayExpress
2009-11-03 | GSE16879 | GEO
| GSE73661 | GEO
2014-08-04 | E-GEOD-12251 | ExpressionAtlas
2011-09-16 | E-GEOD-23597 | ArrayExpress
2011-07-22 | GSE23597 | GEO